GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...
GSK (GSK) plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization, STAT’s John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle ...
1 in 3 people will get shingles in their lifetime; People with diabetes are 38% more likely to contract shingles [1] People ...
New York Post on MSN3d
FDA proposes ending use of popular decongestant in cold medicinesThe US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...
(Reuters) -The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback